**Suppl 2. C**ontinued: baseline characteristics of included studies.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ID | Groups | NO | Thiopurine treatment n(%) | Anti-TNF treatment n(%) | Ileocecal resection n(%) | Ileal involvement n(%) | Ileocolonic involvement n(%) | CDAI mean(SD) | CRP (mg/dL) mean(SD) | C4 (ng/mL) mean(SD) | Frequency of liquid stools/day mean(SD) | FGF19, pmol/L mean(SD) |
|  |
| Appleby et al. 2017 [16] | Cholestyramine (1 g/day) | 7 |  |  |  |  |  |  |  | 55.4 (113.93) |  | 227.6 (336.48) |  |
| Cholestyramine (250 mg/day) | 6 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 50.8 (127.04) | \_ | 317.5 (758.57) |  |
| Placebo | 6 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 27.3 (48.86) | \_ | 209.6 (343.6) |  |
| Beigel et al. 2014 [17] | Colesevelam  | 15 | 4 (26.7) | 10 (66.7) | 8 (53.3) | 15 (100) | 11 (73.3) | 115.3 (31.1) | 0.36 (0.14) | 232.2\*10^3 (101\*10^3) | 4.7 (0.9) | \_ |  |
| Placebo | 11 | 1 (9.0) | 4 (36.4) | 5 (45.5) | 15 (100) | 7 (63.6) | 101.8 (32.1) | 0.24 (0.12) | 198.3\*10^3 (85.4\*10^3) | 4.2 (0.96) | \_ |  |
| Camilleri et al. 2020 | Tropifexor (60 μg/day)-placebo | 10 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 50.6 (45.85) | \_ | 103.5 (74.58) |  |
| Placebo-tropifexor (60 μg/day) | 10 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 45.8 (45.59) | \_ | 108.5 (74.33) |  |
| Devarakonda et al. 2019 | Colesevelam  | 17 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 34.67 (16.16) | \_ |  |
| Cholestyramine | 10 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 19.8 (18.9) | \_ |  |
| Loperamide | 12 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 15.67 (15.5) | \_ |  |
| Colesevelam and Loperamide | 5 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 21.8 (49.8) | \_ |  |
| Kårhus et al. 2022 [20] | Liraglutide | 25 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 54.7 (29.34) | 3·54 (1.33) | 80.4 (48.85) |  |
| Colesevelam | 25 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 54.7 (29.34) | 3·54 (1.33) | 80.4 (48.85) |  |
| Odunsi–Shiyanbade et al. 2010 (B) | Colesevelam | 12 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 28.47 (25) | \_ | \_ |  |
| Placebo | 12 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 24.8 (27.8) | \_ | \_ |  |
| Vijayvargiya 2020 | Colesevelam  | 15 | \_ | \_ | \_ | \_ | \_ | \_ | \_ | 55.8 (39.9) | 3.7 (2.2) | 59.1 (50.7) |  |